FM
ITRM

Frazier Management’s Iterum Therapeutics ITRM Stock Holding History

Frazier Management’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-102,554
Closed -$2.17M – 37
2021
Q1 		$2.17M Hold
102,554
– – 0.17% 33
2020
Q4 		$1.52M Hold
102,554
– – 0.12% 33
2020
Q3 		$1.61M Hold
102,554
– – 0.15% 29
2020
Q2 		$1.83M Hold
102,554
– – 0.16% 24
2020
Q1 		$4.17M Hold
102,554
– – 0.47% 17
2019
Q4 		$6.92M Hold
102,554
– – 1.16% 13
2019
Q3 		$8.88M Hold
102,554
– – 2.78% 12
2019
Q2 		$10.6M Hold
102,554
– – 2.71% 11
2019
Q1 		$12.2M Hold
102,554
– – 2.93% 11
2018
Q4 		$7.71M Hold
102,554
– – 1.99% 11
2018
Q3 		$10.3M Hold
102,554
– – 1.89% 13
2018
Q2 		$16.4M Buy
+102,554
New +$18.5M 3.4% 9

Other funds holding ITRM

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
CPX
Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
KFS
Kelly Financial Services Braintree, Massachusetts $467M AUM 21.13% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
QI
QS Investors New York $8.47B AUM 30.71% 1-Year Est. Return
FNBT
FineMark National Bank & Trust Fort Myers, Florida $3.2B AUM 18.28% 1-Year Est. Return
GC
Grimes & Company Westborough, Massachusetts $3.61B AUM 18.46% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Frazier Management's ITRM Position: Q2 2021 in Review

Frazier Management sold out of Iterum Therapeutics (ITRM) in Q2 2021, closing a stake of 102,554 shares — an estimated $2.17M sold.

Frazier Management first reported a position in ITRM in Q2 2018 and held it in 12 quarters. The position peaked at $16.4M in Q2 2018. 44 funds tracked by Wall St. Rank hold ITRM as of Q2 2021.

  • Frazier Management reported no remaining Iterum Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Frazier Management sold 102,554 Iterum Therapeutics shares in Q2 2021, an estimated $2.17M.
  • Frazier Management first reported a position in Iterum Therapeutics in Q2 2018 and held it in 12 quarters.
  • Frazier Management's Iterum Therapeutics position peaked at $16.4M in Q2 2018.
  • 44 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q2 2021.

Based on Frazier Management's 13F filing for Q2 2021, filed 11 Aug 2021.